HRP20211249T1 - Inhibitori tirozin kinaze - Google Patents
Inhibitori tirozin kinaze Download PDFInfo
- Publication number
- HRP20211249T1 HRP20211249T1 HRP20211249TT HRP20211249T HRP20211249T1 HR P20211249 T1 HRP20211249 T1 HR P20211249T1 HR P20211249T T HRP20211249T T HR P20211249TT HR P20211249 T HRP20211249 T HR P20211249T HR P20211249 T1 HRP20211249 T1 HR P20211249T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- lymphoma
- disease
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 208000007465 Giant cell arteritis Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 206010043207 temporal arteritis Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical group OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- DAFSJBDWNCQDGX-LJQANCHMSA-N 4-amino-1-[(3R)-1-(2-fluoroprop-2-enoyl)piperidin-3-yl]-3-(4-phenoxyphenyl)imidazo[4,5-c]pyridin-2-one Chemical compound NC1=NC=CC2=C1N(C(N2[C@H]1CN(CCC1)C(C(=C)F)=O)=O)C1=CC=C(C=C1)OC1=CC=CC=C1 DAFSJBDWNCQDGX-LJQANCHMSA-N 0.000 claims 1
- YMALYAHRSSETHN-IBGZPJMESA-N 4-amino-3-(4-phenoxyphenyl)-1-[[(2S)-1-prop-2-enoylpyrrolidin-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound C(C=C)(=O)N1[C@@H](CCC1)CN1C(N(C=2C(=NC=CC=21)N)C1=CC=C(C=C1)OC1=CC=CC=C1)=O YMALYAHRSSETHN-IBGZPJMESA-N 0.000 claims 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000000209 Isaacs syndrome Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 206010071579 Neuronal neuropathy Diseases 0.000 claims 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 206010003882 axonal neuropathy Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000019479 dysautonomia Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004476 heterocycloamino group Chemical group 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- -1 piperidinyl carbon Chemical compound 0.000 claims 1
- 208000018290 primary dysautonomia Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Claims (20)
1. Spoj formule (I):
[image]
gdje:
R1 i R2 su neovisno vodik, alkil, alkoksi, haloalkil, ili halo;
X je -O-;
Ar je fenil opcionalno supstituiran s jednim, dva, ili tri supstituenta neovisno izabranih između alkil, halo, haloalkil, alkoksi, i hidroksi;
A je -CR3-, pri čemu R3 je vodik, alkil, ciklopropil, halo, haloalkil, haloalkoksi, alkoksi, ili cijano;
Y je veza ili alkilen;
prsten Z je heterocikloamino opcionalno supstituiran s jednim ili dva supstituenta neovisno izabranih između alkil, hidroksi, alkoksi, i fluoro;
R5 je grupa formule (i) ili (iv):
[image]
gdje:
Ra je vodik ili fluoro;
svaki Rb je neovisno vodik ili alkil; i
Rc je vodik; i/ili
njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1 i/ili njegova farmaceutski prihvatljiva sol, gdje je R3 vodik.
3. Spoj prema zahtjevu 1 ili zahtjevu 2 i/ili njegova farmaceutski prihvatljiva sol, gdje je -X-Ar vezan za ugljik na poziciji 4 fenilnog prstena, ugljik u fenilnom prstenu je vezan za N cikličnog prstena uree prstena u poziciji 1.
4. Spoj prema bilo kojem od zahtjeva 1 do 3 i/ili njegova farmaceutski prihvatljiva sol, pri čemu R1 i R2 su neovisno vodik ili halo.
5. Spoj prema bilo kojem od zahtjeva 1 do 4 i/ili njegova farmaceutski prihvatljiva sol, gdje Y je veza, i prsten Z je piperidinil pri čemu atom ugljika na poziciji 3 piperidinil prstena je vezan za atom dušika cikličnog prstena uree.
6. Spoj prema zahtjevu 5 i/ili njegova farmaceutski prihvatljiva sol, pri čemu stereokemija na ugljiku piperidinila vezanog za dušik ciklične uree je (R).
7. Spoj prema zahtjevu 1 ili zahtjevu 6 i/ili njegova farmaceutski prihvatljiva sol, pri čemu R5 je grupa formule (i).
8. Spoj prema zahtjevu 1 izabran od (R)-1-(1-akriloilpiperidin-3-il)-4-amino-3-(4-fenoksifenil)-1H-imidazo[4,5-c]piridin-2(3H)-ona i/ili njegove farmaceutski prihvatljive soli.
9. Spoj prema zahtjevu 1 izabran od (R)-4-amino-1-(1-(but-2-inoil)piperidin-3-il)-3-(4-fenoksifenil)-1H-imidazo[4,5-c]piridin-2(3H)-ona i/ili njegove farmaceutski prihvatljive soli.
10. Spoj prema zahtjevu 1 izabran od (S)-1-((1-akriloilpirolidin-2-il)metil)-4-amino-3-(4-fenoksifenil)-1H-imidazo[4,5-c]piridin-2(3H)-ona i/ili njegove farmaceutski prihvatljive soli.
11. Spoj prema zahtjevu 1 izabran od (S)-4-amino-1-((1-(but-2-inoil)pirolidin-2-il)metil)-3-(4-fenoksifenil)-1H-imidazo[4,5-c]piridin-2(3H)-ona i/ili njegove farmaceutski prihvatljive soli.
12. Spoj prema zahtjevu 1 izabran od (R)-4-amino-1-(1-(2-fluoroakriloil)piperidin-3-il)-3-(4-fenoksifenil)-1H-imidazo[4,5-c]piridin-2(3H)-ona i/ili njegove farmaceutski prihvatljive soli.
13. Farmaceutski sastav koji se sastoji iz spoja i/ili farmaceutski prihvatljive soli prema bilo kojem od zahtjeva 1 do 12 i farmaceutski prihvatljive pomoćne tvari.
14. Farmaceutski sastav koji se sastoji iz spoja i/ili farmaceutski prihvatljive soli prema zahtjevu 8 i farmaceutski prihvatljive pomoćne tvari.
15. Lijek koji se sastoji iz spoja i/ili farmaceutski prihvatljive soli prema zahtjevu 8 i farmaceutski prihvatljive pomoćne tvari.
16. Spoj i/ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 12 za upotrebu kao lijek.
17. Spoj i/ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 12 za upotrebu u liječenju bolesti izabrane između autoimune bolesti, upalne bolesti, ili karcinoma kod sisavaca kojima je potrebno.
18. Spoj i/ili njegova farmaceutski prihvatljiva sol za upotrebu prema zahtjevu 17, pri čemu je bolest akutni nekrotizirajući hemoragični leukoencefalitis, akutni diseminirani encefalomijelitis, autoimuna bolest unutarnjeg uha (AIED), autoimuna retinopatija, aksonalne i neuronske neuropatije, kroničnaupalna demijelinizirajuća polineuropatija (CIDP), demijelinizirajuće neuropatije, Devićeva bolest (neuromyelitis optica), eksperimentalni alergijski encefalomijelitis, arteritis gigantskih stanica (temporalni arteritis), Guillain-Barreov sindrom sindrom, Lambert-Eaton sindrom, kronična Meniereova bolest, miastenia gravis, neuromiotonija, opsoklonus-mioklonus sindrom, optički neuritis, paraneoplastična cerebelarna degeneracija, periferna neuropatija, perivenozni encefalomijelitis, sindrom nemirnih nogu, sindrom ukočene osobe, simpatička oftalmija, Takayasuov arteritis, temporalni arteritis/arteritis divovskih stanica, transverzalni mijelitis, multipla skleroza, disautonomija, starosna makularna degeneracija povezana (mokra i suha), transplantacija rožnice, encefalitis, meningitis, vaskulitis, ili sistemski eritematozni lupus (SLE).
19. Spoj i/ili njegova farmaceutski prihvatljiva sol za upotrebu prema zahtjevu 17, pri čemu je bolest reumatoidni artritis, psorijazni artritis, lupus, uveitis, miastenija gravis, topla autoimuna hemolitička anemija, Wegenerova granulomatoza, Sjogrenova bolest, Sjogrenov sindrom suhog oka, ne-Sjogrenova bolest suhog oka, psorijaza, pemfigus, urtikarija, ili astma.
20. Spoj i/ili njegova farmaceutski prihvatljiva sol za upotrebu prema zahtjevu 17, pri čemu je karcinom difuzni limfom velikih B stanica, folikularni limfom, kronični limfocitni limfom, kronična limfocitna leukemija, B-stanična prolimfocitna leukemija, mali limfocitni limfom (SLL),višestruki mijelom, ne-Hodgkinov limfom B stanica, limfoplazmacitni limfom/Waldenstrom makroglobulinemija, limfom marginalne zone slezene, mijelom plazma stanice, plazmacitom, ekstranodalni B-stanični limfom marginalne zone, nodalni B-stanični limfom marginalne zone, limfom stanica plašta (mantle), medijastinalni (timusni) limfom velikih B-stanica, intravaskularni limfom velikih B-stanica, primarni izljevni limfom, burkittov limfom/leukemija, ili limfomatoidna granulomatoza.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562170547P | 2015-06-03 | 2015-06-03 | |
US201562271689P | 2015-12-28 | 2015-12-28 | |
PCT/US2016/035588 WO2016196840A1 (en) | 2015-06-03 | 2016-06-02 | Tyrosine kinase inhibitors |
EP16728566.7A EP3303334B1 (en) | 2015-06-03 | 2016-06-02 | Tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211249T1 true HRP20211249T1 (hr) | 2021-11-12 |
Family
ID=56118090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211249TT HRP20211249T1 (hr) | 2015-06-03 | 2021-08-04 | Inhibitori tirozin kinaze |
Country Status (32)
Country | Link |
---|---|
US (4) | US20180162861A1 (hr) |
EP (3) | EP4112618A1 (hr) |
JP (2) | JP6646072B2 (hr) |
KR (1) | KR102552653B1 (hr) |
CN (2) | CN106459049B (hr) |
AU (2) | AU2016270973B2 (hr) |
CA (1) | CA2987335A1 (hr) |
CL (2) | CL2017003073A1 (hr) |
CO (1) | CO2017012947A2 (hr) |
CR (1) | CR20170593A (hr) |
DK (1) | DK3303334T3 (hr) |
DO (1) | DOP2017000279A (hr) |
EA (1) | EA039006B1 (hr) |
ES (1) | ES2878030T3 (hr) |
HK (1) | HK1252378A1 (hr) |
HR (1) | HRP20211249T1 (hr) |
HU (1) | HUE055419T2 (hr) |
IL (2) | IL255946A (hr) |
LT (1) | LT3303334T (hr) |
MX (2) | MX2017015470A (hr) |
MY (1) | MY190548A (hr) |
PE (1) | PE20180521A1 (hr) |
PH (1) | PH12017502203A1 (hr) |
PL (1) | PL3303334T3 (hr) |
PT (1) | PT3303334T (hr) |
RS (1) | RS62290B1 (hr) |
SG (1) | SG10201912443XA (hr) |
SI (1) | SI3303334T1 (hr) |
TN (1) | TN2017000501A1 (hr) |
TW (2) | TWI810582B (hr) |
UA (1) | UA124090C2 (hr) |
WO (1) | WO2016196840A1 (hr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104159635B (zh) | 2012-02-27 | 2018-09-25 | 奥雷制药有限公司 | 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物 |
US9266895B2 (en) | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
JP6581506B2 (ja) | 2013-11-29 | 2019-09-25 | 株式会社ダイゾー | 内容物収容容器、それを用いた内容物収容製品、吐出製品および吐出装置 |
MX2016010754A (es) | 2014-02-21 | 2017-03-03 | Principia Biopharma Inc | Sales y forma solida de un inhibidor btk. |
PL3233103T3 (pl) | 2014-12-18 | 2021-04-19 | Principia Biopharma Inc. | Leczenie pęcherzycy |
ES2878030T3 (es) * | 2015-06-03 | 2021-11-18 | Principia Biopharma Inc | Inhibidores de tirosina cinasa |
EP3313839A1 (en) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
BR112018077503A2 (pt) | 2016-06-29 | 2019-04-09 | Principia Biopharma Inc. | formulações de liberação modificada de 2-[3-[4-amino-3-(2-fluoro-4- fenoxi-fenil)pirazolo [3,4-d]pirimidin-1-il]piperidino-1- carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il] pent-2-enenitrila |
CN109790164B (zh) * | 2016-07-25 | 2022-01-25 | 内尔维亚诺医疗科学公司 | 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物 |
US10314844B2 (en) * | 2017-02-24 | 2019-06-11 | Gilead Sciences, Inc. | Inhibitors of Bruton's tyrosine kinase |
US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
CR20210045A (es) | 2018-07-25 | 2021-06-18 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
CN112689637B (zh) * | 2018-09-13 | 2023-11-10 | 橘生药品工业株式会社 | 咪唑并吡啶酮化合物 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN113045484B (zh) * | 2019-12-27 | 2024-01-26 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法 |
CN113149891B (zh) * | 2020-01-07 | 2024-02-02 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)乙醇的制备方法 |
WO2021150476A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CA3172749A1 (en) * | 2020-03-30 | 2021-10-07 | Lois B. ROSENBERGER | Pediatric formulation of tyrosine kinase inhibitors |
BR112023002031A2 (pt) | 2020-08-14 | 2023-03-07 | Novartis Ag | Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos |
US20220133734A1 (en) | 2020-11-02 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
AU2021398051A1 (en) * | 2020-12-10 | 2023-07-27 | Genzyme Corporation | Crystal form of tolebrutinib, preparation method therefor and use thereof |
CA3206176A1 (en) * | 2020-12-23 | 2022-06-30 | Catherine ARABEYRE | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof |
WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
WO2022218430A1 (zh) * | 2021-04-16 | 2022-10-20 | 南京明德新药研发有限公司 | 咪唑并吡啶类化合物及其应用 |
EP4328226A1 (en) | 2021-04-23 | 2024-02-28 | Hangzhou Solipharma Co., Ltd. | Tolebrutinib crystal form, amorphous form, preparation method therefor and use thereof |
CN117412749A (zh) | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
KR20240021217A (ko) | 2021-06-11 | 2024-02-16 | 젠자임 코포레이션 | 톨레브루티닙의 결정질 형태 및 이의 제조 방법 및 용도 |
WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
WO2023049420A1 (en) * | 2021-09-24 | 2023-03-30 | Donaldson Chadwick | Dry powder foamable formulations for delivery of medicaments through the mucosa |
TW202334146A (zh) | 2021-12-21 | 2023-09-01 | 美商健臻公司 | (r)-1-(1-丙烯醯基哌啶-3-基)-4-胺基-3-(4-苯氧基苯基)-1h-咪唑並[4,5-c]吡啶-2(3h)-酮及其衍生物的晶型 |
WO2023172663A1 (en) * | 2022-03-09 | 2023-09-14 | Teva Pharmaceuticals International Gmbh | Solid state forms of tolebrutinib and of tolebrutinib salts |
US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
WO2023244587A1 (en) * | 2022-06-14 | 2023-12-21 | Genzyme Corporation | Methods of making tolebrutinib |
WO2023249980A1 (en) * | 2022-06-22 | 2023-12-28 | Genzyme Corporation | Methods of making modified btk inhibitors |
WO2024006406A1 (en) | 2022-06-30 | 2024-01-04 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
WO2024081168A1 (en) | 2022-10-11 | 2024-04-18 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
AU2005284835A1 (en) * | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
WO2006086634A2 (en) * | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
EP2700638A1 (en) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
RU2012114902A (ru) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | Конъюгаты и ингибиторы протеинкиназы |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
EP2578585B1 (en) * | 2010-05-31 | 2016-07-20 | ONO Pharmaceutical Co., Ltd. | Purinone derivative as btk kinase inhibitor |
BR112013028846B1 (pt) * | 2011-05-17 | 2021-12-07 | Principia Biopharma Inc | Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica |
US9187487B2 (en) * | 2011-05-17 | 2015-11-17 | Principia Biopharma, Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
PL2710007T3 (pl) * | 2011-05-17 | 2020-06-01 | The Regents Of The University Of California | Inhibitory kinazy |
DK2786996T3 (en) * | 2011-11-29 | 2016-12-19 | Ono Pharmaceutical Co | Hydrochloride PURINONDERIVAT |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
CN104487441B (zh) * | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
RS62233B1 (sr) | 2012-07-11 | 2021-09-30 | Blueprint Medicines Corp | Inhibitori receptora fibroblast faktora rasta |
US9266895B2 (en) * | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
US20140142099A1 (en) * | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
ES2878030T3 (es) * | 2015-06-03 | 2021-11-18 | Principia Biopharma Inc | Inhibidores de tirosina cinasa |
CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
WO2017066014A1 (en) | 2015-10-14 | 2017-04-20 | Sunnylife Pharma Inc. | Bruton's tyrosine kinase inhibitors |
-
2016
- 2016-06-02 ES ES16728566T patent/ES2878030T3/es active Active
- 2016-06-02 KR KR1020177037609A patent/KR102552653B1/ko active IP Right Grant
- 2016-06-02 RS RS20211083A patent/RS62290B1/sr unknown
- 2016-06-02 CN CN201680000891.8A patent/CN106459049B/zh active Active
- 2016-06-02 WO PCT/US2016/035588 patent/WO2016196840A1/en active Application Filing
- 2016-06-02 TW TW110121130A patent/TWI810582B/zh active
- 2016-06-02 CN CN202011284728.3A patent/CN113149983B/zh active Active
- 2016-06-02 TN TNP/2017/000501A patent/TN2017000501A1/en unknown
- 2016-06-02 PT PT167285667T patent/PT3303334T/pt unknown
- 2016-06-02 CR CR20170593A patent/CR20170593A/es unknown
- 2016-06-02 EP EP22188609.6A patent/EP4112618A1/en active Pending
- 2016-06-02 SG SG10201912443XA patent/SG10201912443XA/en unknown
- 2016-06-02 TW TW105117466A patent/TWI732765B/zh active
- 2016-06-02 JP JP2017562758A patent/JP6646072B2/ja active Active
- 2016-06-02 PE PE2017002512A patent/PE20180521A1/es unknown
- 2016-06-02 US US15/578,623 patent/US20180162861A1/en not_active Abandoned
- 2016-06-02 EP EP16728566.7A patent/EP3303334B1/en active Active
- 2016-06-02 PL PL16728566T patent/PL3303334T3/pl unknown
- 2016-06-02 CA CA2987335A patent/CA2987335A1/en active Pending
- 2016-06-02 SI SI201631244T patent/SI3303334T1/sl unknown
- 2016-06-02 MX MX2017015470A patent/MX2017015470A/es unknown
- 2016-06-02 LT LTEPPCT/US2016/035588T patent/LT3303334T/lt unknown
- 2016-06-02 DK DK16728566.7T patent/DK3303334T3/da active
- 2016-06-02 MX MX2021006571A patent/MX2021006571A/es unknown
- 2016-06-02 HU HUE16728566A patent/HUE055419T2/hu unknown
- 2016-06-02 EP EP21169631.5A patent/EP3912979A1/en active Pending
- 2016-06-02 MY MYPI2017704576A patent/MY190548A/en unknown
- 2016-06-02 AU AU2016270973A patent/AU2016270973B2/en active Active
- 2016-06-02 EA EA201792529A patent/EA039006B1/ru unknown
- 2016-06-02 UA UAA201712794A patent/UA124090C2/uk unknown
-
2017
- 2017-01-19 US US15/410,716 patent/US9688676B2/en active Active
- 2017-11-27 IL IL255946A patent/IL255946A/en active IP Right Grant
- 2017-12-01 DO DO2017000279A patent/DOP2017000279A/es unknown
- 2017-12-01 CL CL2017003073A patent/CL2017003073A1/es unknown
- 2017-12-01 PH PH12017502203A patent/PH12017502203A1/en unknown
- 2017-12-15 CO CONC2017/0012947A patent/CO2017012947A2/es unknown
-
2018
- 2018-09-11 HK HK18111674.0A patent/HK1252378A1/zh unknown
-
2019
- 2019-07-31 CL CL2019002150A patent/CL2019002150A1/es unknown
-
2020
- 2020-01-08 JP JP2020001139A patent/JP6985433B2/ja active Active
- 2020-05-26 AU AU2020203447A patent/AU2020203447B2/en active Active
- 2020-09-23 US US17/029,184 patent/US20210171526A1/en not_active Abandoned
- 2020-12-07 IL IL279258A patent/IL279258B/en unknown
-
2021
- 2021-08-04 HR HRP20211249TT patent/HRP20211249T1/hr unknown
-
2022
- 2022-10-27 US US17/974,613 patent/US20230151012A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211249T1 (hr) | Inhibitori tirozin kinaze | |
JP2018516935A5 (hr) | ||
HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
HRP20210693T1 (hr) | Inhibitori beta-laktamaze | |
HRP20170456T1 (hr) | Novi kondenzirani derivati pirimidina, namijenjeni inhibiranju aktivnosti tirozinske kinaze | |
PE20161443A1 (es) | Compuestos | |
HRP20200681T1 (hr) | Ciklički eter pirazol-4-il-heterociklil-karboksamidni spojevi i postupci njihove upotrebe | |
HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
HRP20180863T1 (hr) | Aktivatori piruvat kinaze za uporabu u terapiji | |
HRP20120824T1 (hr) | Derivati 4-(3-aminopirazol) pirimidina za uporabu kao inhibitori tirozin kinaze u lijeäśenju karcinoma | |
HRP20180483T1 (hr) | Spoj kinolona | |
NZ629442A (en) | Heterocyclyl compounds as mek inhibitors | |
JP2016506962A5 (hr) | ||
AR099312A1 (es) | Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza | |
CO7160063A2 (es) | 7h-pirrolo[2,3-d] pirimidinas 4 - (amino-substituidas) novedosas como inhibidores de lrrk2 | |
PE20161246A1 (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
JP2016528298A5 (hr) | ||
MX2014006210A (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
NZ588830A (en) | Inhibitors of protein kinases | |
NZ749437A (en) | Processes and intermediates for making a jak inhibitor | |
MY168201A (en) | Agricultural And Horticultural Fungicidal Composition | |
JP2017530185A5 (hr) | ||
EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
PE20160173A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO |